Innoviva PE Ratio 2010-2024 | INVA

Current and historical p/e ratio for Innoviva (INVA) from 2010 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Innoviva PE ratio as of May 22, 2024 is 7.05.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Innoviva PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2024-05-23 15.79 7.11
2024-03-31 15.24 $2.22 6.86
2023-12-31 16.04 $2.18 7.36
2023-09-30 12.99 $0.44 29.52
2023-06-30 12.73 $2.26 5.63
2023-03-31 11.25 $2.29 4.91
2022-12-31 13.25 $2.07 6.40
2022-09-30 11.61 $3.19 3.64
2022-06-30 14.76 $1.29 11.44
2022-03-31 19.35 $2.14 9.04
2021-12-31 17.25 $2.78 6.21
2021-09-30 16.71 $3.12 5.36
2021-06-30 13.41 $2.48 5.41
2021-03-31 11.95 $2.27 5.26
2020-12-31 12.39 $2.02 6.13
2020-09-30 10.45 $1.96 5.33
2020-06-30 13.98 $2.06 6.79
2020-03-31 11.76 $1.71 6.88
2019-12-31 14.16 $1.43 9.90
2019-09-30 10.54 $3.35 3.15
2019-06-30 14.56 $3.42 4.26
2019-03-31 14.03 $3.56 3.94
2018-12-31 17.45 $3.52 4.96
2018-09-30 15.24 $1.63 9.35
2018-06-30 13.80 $1.41 9.79
2018-03-31 16.67 $1.23 13.55
2017-12-31 14.19 $1.11 12.78
2017-09-30 14.12 $0.87 16.23
2017-06-30 12.80 $0.78 16.41
2017-03-31 13.83 $0.60 23.05
2016-12-31 10.70 $0.49 21.84
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.004B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $763.090B 110.29
Novo Nordisk (NVO) Denmark $601.464B 46.22
Johnson & Johnson (JNJ) United States $369.425B 14.68
Merck (MRK) United States $332.051B 60.42
AbbVie (ABBV) United States $281.850B 14.56
AstraZeneca (AZN) United Kingdom $244.317B 21.24
Novartis AG (NVS) Switzerland $208.406B 14.78
Pfizer (PFE) United States $167.731B 20.84
Sanofi (SNY) $127.391B 12.02